Contineum Therapeutics (CTNM) investor relations material

Key accomplishments and clinical progress

• Executed four clinical studies in the first full year as a public company, including a phase 1b PET receptor occupancy study for PIPE-791 and full enrollment of a phase 1b exploratory study in chronic pain, with data expected in the first half of next year.

• Reported VISTA data for PIPE-307 in relapsing-remitting MS, missing the primary endpoint but providing valuable insights into M1 receptor antagonism.

• Initiating a phase two clinical proof-of-concept study in idiopathic pulmonary fibrosis (IPF) with PIPE-791, designed to be operationally similar to a phase three study.

Scientific rationale and differentiation

• LPA1 receptor antagonism in IPF is supported by seminal research showing LPA upregulation leads to fibrosis and inflammation; inhibiting LPA1 can reduce these effects.

• PIPE-791 offers high receptor occupancy and QD dosing, differentiating it from competitors like BMS's BID drug, with potential for better efficacy and safety.

• Preclinical and human tissue studies demonstrated reductions in fibrosis markers and confirmed LPA1 upregulation in IPF tissue, supporting the clinical approach.

Market landscape and opportunity

• Current IPF treatments have significant tolerability issues, leading to high rates of patient refusal and discontinuation; the market is seen as untapped despite Ofev's $4B+ annual sales.

• New entrants like BI's nerandomilast face challenges, and there is a need for therapies with better safety and efficacy profiles.

• LPA1 antagonists are positioned to become the backbone of IPF and PPF therapy, with potential for polypharmacy approaches.